Gene · 9201
Papers1,726
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,726
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Role of Non-Coding RNAs in the Regulation of Oncogenic Pathways in Breast and Gynaecological Cancers. | Noncoding RNA | 2025 | 40863727 | PubTator, text mining | PubMed |
| DCLK1 isoform (DCLK1-S) as a critical player in promoting inflammation, tissue remodeling, and EMT in mouse models of colitis. | PLoS Pathog | 2025 | 40839695 | PubTator, text mining | PubMed |
| Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma. | Cell Death Dis | 2025 | 40775208 | PubTator, text mining | PubMed |
| Exploring microRNA targeting as a promising approach for solid tumor treatment. | Front Oncol | 2025 | 40761244 | PubTator, text mining | PubMed |
| From heterogeneity to hope: emerging markers in triple-negative breast cancer research. | Med Oncol | 2025 | 40670829 | PubTator, text mining | PubMed |
| In-vitro immunomodulatory efficacy of extracellular vesicles derived from TGF-β1/IFN-γ dual licensed human bone marrow mesenchymal stromal cells. | Stem Cell Res Ther | 2025 | 40629458 | PubTator, text mining | PubMed |
| Corrigendum to "Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer" [Cancer Lett. 2023 Dec 1;578:216437]. | Cancer Lett | 2025 | 40610305 | PubTator, text mining | PubMed |
| The RNA-binding protein DDX39B promotes colorectal adenocarcinoma progression by stabilizing DCLK1. | Hum Mol Genet | 2025 | 40583564 | PubTator, text mining | PubMed |
| The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing. | Adv Mater | 2025 | 40576525 | PubTator, text mining | PubMed |
| Balancing Regeneration and Resistance: Targeting DCLK1 to Mitigate Gastrointestinal Radiation Injury and Oncogenesis. | Cancers (Basel) | 2025 | 40563698 | PubTator, text mining | PubMed |
| [Prognostic value of molecular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations]. | Arkh Patol | 2025 | 40531562 | PubTator, text mining | PubMed |
| Generation and functional characterization of tuft cells in non-human primate pancreatic ducts through organoid culture systems. | Front Cell Dev Biol | 2025 | 40395933 | PubTator, text mining | PubMed |
Doublecortin-like kinase 1, regulated by STIP1 homology and U-box containing protein 1 or Sp1 transcription factor, affects the malignant behaviors and drug sensitivity in adriamycin-resistant breast cancer cells. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | 40257489 | PubTator, text mining | PubMed |
| Retraction Note: Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. | Mol Cancer | 2025 | 40253332 | PubTator, text mining | PubMed |
| Evolving insights into pancreatic tumor initiation and progression through DCLK1-expressing tuft cells. | Dev Cell | 2025 | 40132546 | PubTator, text mining | PubMed |
| Clinical significance of "S" isoform of DCLK1 in different gastric cancer subtypes using newly produced monoclonal antibody. | Cancer Biomark | 2025 | 40109216 | PubTator, text mining | PubMed |
| Carcinoma arising in microglandular adenosis of the breast: clinicopathological and genetic analysis. | J Clin Pathol | 2025 | 40081883 | PubTator, text mining | PubMed |
| DCLK1 in gastrointestinal cancer: A driver of tumor progression and a promising therapeutic target. | Int J Cancer | 2025 | 40056091 | PubTator, text mining | PubMed |
| Acute tuft cell ablation in mice induces malabsorption and alterations in secretory and immune cell lineages in the small intestine. | Physiol Rep | 2025 | 40051209 | PubTator, text mining | PubMed |
| DCLK1-mediated regulation of invadopodia dynamics and matrix metalloproteinase trafficking drives invasive progression in head and neck squamous cell carcinoma. | Mol Cancer | 2025 | 39994636 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9201/papers?page=3